We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prostate Cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background and study aims
Prostate cancer is the most common cancer in men in the UK. It usually develops slowly, so there may be no signs for many years.
PEARLS aims to improve patient outcomes by treating patients whose cancer has spread to the lymph nodes with radiotherapy to an extended area than is currently used. The investigators think that by extending radiation to cover a wider area where recurrences can often occur may improve control of the cancer. There is currently no standard management for prostate cancer patients who present at diagnosis with cancer having spread to the lymph nodes in the abdomen. Previous studies have indicated that it is safe to treat the prostate and pelvic areas with radiotherapy. There have been no recent studies using modern radiotherapy technology to treat larger areas within the abdomen.
PEARLS will assess the differences in side effects for patients treated with standard or an extended radiotherapy area to make sure these are acceptable and if they are, we will include more patients in the study to see if the extended radiotherapy treatment helps to control the cancer better.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36238579/ (added 04/06/2024)
You can take part if:
You may not be able to take part if:
1. Prior radiotherapy to the prostate or pelvis; prior bilateral orchiectomy; radical prostatectomy.2. For those patients who have received docetaxel chemotherapy or are receiving androgen receptor targeted therapy, there should be no ongoing CTCAE grade 2 or greater GI toxicity relating to this systemic therapy.3. Medical conditions (non-prostate cancer related) expected to limit life expectancy to < 5 years.4. Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artefacts and would make pelvic node planning more difficult.5. Medical conditions likely to make radiotherapy inadvisable e.g. inflammatory bowel disease, intractable urinary symptoms, previous colorectal surgery.6. Previous malignancy within the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin or small renal masses under surveillance), or if previous malignancy is expected to significantly compromise 5 year survival.7. Any other contraindication to external beam radiotherapy to the para-aortic and/or pelvic region.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Shama
Hassan
+44 (0)20 8722 4183
pearls-icrctsu@icr.ac.uk
The study is sponsored by Institute of Cancer Research and funded by Cancer Research UK.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 48429
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
